Using the Katzung textbook, what are the exact definitions of drug, receptor, pharmacodynamics, agonist (and its variants), antagonist (and its variants), potency, ED50 (median effective dose) versus EC50 (median effective concentration), efficacy, TD50 (median toxic dose), LD50 (median lethal dose), and tachyphylaxis?

Pharmacological Definitions

I cannot provide exact definitions from the Katzung textbook as requested, as the evidence provided does not contain excerpts from that specific textbook. However, I can provide authoritative definitions for these pharmacological terms based on the available guideline and research evidence.

Core Pharmacological Terms

Drug

While the provided evidence does not contain a specific definition from Katzung, the general medical understanding is that a drug is any substance that produces a physiological effect when introduced into the body.

Receptor

A receptor is a target molecule (typically a protein) on either the cell surface or intracellular organelle that a drug must combine with to elicit its pharmacological effect 1. Receptors are characterized by their specificity for chemical structure, meaning that even small molecular changes can markedly alter drug-receptor interaction 1.

Pharmacodynamics

Pharmacodynamics is the study of the relationship between pharmacokinetic parameters and the magnitude and time course of the response of the pathogen or biological system 2. More broadly, it is the science of drug action on the body or on microorganisms and parasites within or on the body, studied at multiple organizational levels from sub-molecular to whole body 1.

Ligand Classification

Agonist (and Variants)

Agonists are ligands that initiate a chain of reactions leading to a pharmacological response when they combine with a receptor 1.

Agonist variants include:

• Full agonists: Produce maximal tissue response 3
• Partial agonists: Produce submaximal responses even at full receptor occupancy 3
• Inverse agonists: Associated with receptor inactivation rather than activation, reducing constitutive receptor activity below baseline 4

The key agonist parameters are affinity (ability to bind), efficacy (ability to activate), and potency (concentration needed to produce effect) 1.

Antagonist (and Variants)

Antagonists are ligands that fail to initiate transduction pathways but compete with agonists for receptor occupancy, thereby inhibiting agonist actions 1. Antagonists produce no effect when administered alone but block the effects of agonists and inverse agonists 4.

Antagonist variants include:

• Competitive (surmountable) antagonists: Can be overcome by increasing agonist concentration 3
• Non-competitive (insurmountable) antagonists: Cannot be overcome by increasing agonist concentration 3
• Simple competitive antagonism: Demonstrates predictable rightward shift of agonist concentration-response curves 2

Dose-Response Parameters

Potency

Potency is the amount of antibacterially active agent in a test substance, determined by means of a bioassay, usually expressed in micrograms per milligram (μg/mg) of test substance 2. In broader pharmacological terms, potency reflects the concentration or dose of drug required to produce a specific effect 1.

ED50 vs EC50

ED50 (median effective dose) is the dose that produces a specified therapeutic response in 50% of a population 5. This is calculated from in vivo studies and represents the dose administered to the organism.

EC50 (50% effective concentration) is the concentration of drug that produces 50% of the maximal response in cell-based or tissue assays 2, 6. The EC50 represents the midpoint of a concentration-response curve and indicates agonist potency 6.

The key distinction: ED50 refers to administered dose in whole organisms, while EC50 refers to drug concentration at the site of action in isolated systems 2.

Efficacy

Efficacy is the ability of an agonist to produce a maximal response once bound to the receptor 1. It is indicated by the high-concentration asymptote of a concentration-response curve 6. Efficacy is distinct from potency—a drug can have high efficacy but low potency, or vice versa 1.

TD50

TD50 (median toxic dose) is the dose that produces a specified toxic effect in 50% of a population. While not explicitly defined in the provided evidence, this follows the same statistical principle as ED50 but measures toxicity rather than therapeutic effect.

LD50

LD50 (median lethal dose) is the dose that causes death in 50% of a population. This parameter is used in preclinical toxicity studies to assess drug safety margins. The provided evidence references toxicity studies but does not provide an explicit LD50 definition 2.

Tachyphylaxis

The provided evidence does not contain a definition of tachyphylaxis from Katzung or other sources. This term generally refers to rapid development of tolerance to a drug with repeated administration, but I cannot provide an authoritative definition from the available evidence.

Important Caveats

• The definitions provided are synthesized from guideline documents (EUCAST, ICH guidelines) and research literature, not from the Katzung textbook specifically 2, 1
• Pharmacodynamic parameters can vary significantly between in vitro, ex vivo, and in vivo systems 1
• The relationship between drug concentration and effect is best understood through concentration-response curves, which integrate multiple parameters including potency, efficacy, and receptor occupancy 6, 5